Use of biological therapy in patients with rheumatoid arthritis in the Republic of Kazakhstan

Full Text


Aim. To evaluate the clinical efficacy and safety of infliximab (IFM) in patients with rheumatoid arthritis (RA). Subjects and methods. Twelve inpatients (10 women and 2 men) aged 23 to 65 years with a valid diagnosis of RA, the duration of which was 3 years or more, were retrospectively analyzed. DAS28 for RA corresponded to grades II and III in 4 (33.3%) and 8 (66.7%) patients, respectively. Long before the investigation, all the patients used methotrexate in a weekly dose of 15 mg and nonsteroidal anti-inflammatory drugs; 6 patients received methipred in a daily dose of 4-8 mg. IFM was administered intravenously dropwise on the basis of 3 mg/kg weight in 250 ml of isotonic sodium hydrochloride solution during 2 hours at 0, 2, and 6 weeks after therapy initiation and then every 8 weeks. Results. During combination therapy after the first IFM infusion, all the 12 patients were noted to have a positive clinical effect as a significant reduction in the number of tender joints and swollen joints, morning stiffness, erythrocyte sedimentation rate, C-reactive protein, regression of the clinical manifestations of the disease, and its laboratory activity. The therapy was tolerated well by all the patients. According to the EULAR criteria, a good therapeutic effect was observed in 10 (83%) patients and clinical remission was achieved in 2 (17%) patients. According to the ACR criteria, 50 and 70% improvement was seen in 1 (8%) and 9 (75%) patients, respectively. Two (17%) patients achieved remission. Conclusion. Combination therapy with IFM and MT for RA is highly effective, suppresses disease inflammatory activity and joint destruction; furthermore, there may be remission induction.

About the authors

M G Nogaeva

A S Amanzholova


  1. Ревматология. Клинические рекомендации. Под ред. акад. РАМН Насонова Е.Л. М.: ГЭОТАР-Медиа; 2008:26-27.
  2. Попкова Т.В., Новикова Д.С., Писарев В.В., Мач Э.С., Насонов Е.Л. Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите. Научно-практическая ревматология. 2009;47(3):4-11.
  3. Сигидин Я.А., Лукина Г.В. Обобщенный анализ результатов генно-инженерной биологической терапии — поиски новых закономерностей. Научно-практическая ревматология. 2013;51(5): 476-480.
  4. Насонов Е.Л. Генно-инженерные биологические препараты в лечении ревматоидного артрита. М.: ИМА-ПРЕСС; 2013:549.
  5. Каратеев Д.Е. Ритуксимаб в современной терапии ревматодного артрита. Фарматека для практикующих врачей. 2010;5:26-32.
  6. Насонов Е.Л. Каратеев Д.Е. Применение генно-инженерных биологических препаратов для лечения ревматоидного артрита: общая характеристика (лекция). Научно-практическая ревматология 2013;51(2):163-169.
  7. Каратеев Д.Е. Современные возможности достижения клинической ремиссии при ревматоидном артрите. Трудный пациент. 2007;11(5):45-48.
  8. Van der Kooij SM, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJS, van der Lubbe PAHM, de Beus WM, Grillet BAM, Ronday HK, Huizinga TWJ, Breedveld FC, Dijkmans BAC, Allaart CF. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914-921.
  9. Smolen JS, Aletaha D, Bijlsma Johannes WJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M , Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.
  10. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JWJW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.
  11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes Johanna MW, Hobbs K, Huizinga Tom WJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. Rheumatoid arthritis classification criteria. An American College of Rheumatology/European Leaque Against Rheumatism collaborative initiative. ArthritisRheum. 2010;62:2569-2581.
  12. Felson DT, Smolen JS, Bin Zhang WG, van Tuyl LHD, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewé R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of European Rheumatology/Leaque Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-586.
  13. Ревматология. Национальное руководство. Под ред. акад. РАМН Насонова Е.Л., акад. РАМН Насоновой В.А. М.: ГЭОТАР-Медиа; 2010:292.
  14. Ревматология. Клинические рекомендации. Под ред. акад. РАМН Насонова Е.Л. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа; 2010:182-184.



Abstract: 151

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2015 Nogaeva M.G., Amanzholova A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies